DRG2
Developmentally-regulated GTP-binding protein 2
Also known as: DRG2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P55039
- Gene
- DRG2
- Ensembl
- ENSG00000108591
- Chromosome
- 17
- Canonical length
- 364 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Vesicles,Cytosol
OverviewNCBI Gene
This gene encodes a GTP-binding protein known to function in the regulation of cell growth and differentiation. Read-through transcripts containing this gene and a downstream gene have been identified, but they are not thought to encode a fusion protein. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jan 2012]
Canonical amino-acid sequenceUniProt
364 residues, UniProt reviewed canonical sequence.
>P55039|DRG2
1 MGILEKISEI EKEIARTQKN KATEYHLGLL KAKLAKYRAQ LLEPSKSASS KGEGFDVMKS
61 GDARVALIGF PSVGKSTFLS LMTSTASEAA SYEFTTLTCI PGVIEYKGAN IQLLDLPGII
121 EGAAQGKGRG RQVIAVARTA DVIIMMLDAT KGEVQRSLLE KELESVGIRL NKHKPNIYFK
181 PKKGGGISFN STVTLTQCSE KLVQLILHEY KIFNAEVLFR EDCSPDEFID VIVGNRVYMP
241 CLYVYNKIDQ ISMEEVDRLA RKPNSVVISC GMKLNLDYLL EMLWEYLALT CIYTKKRGQR
301 PDFTDAIILR KGASVEHVCH RIHRSLASQF KYALVWGTST KYSPQRVGLT HTMEHEDVIQ
361 IVKKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DRG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 36 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 36 nTPM
- endometrium: 22 nTPM
- ovary: 22 nTPM
- esophagus: 21 nTPM
- blood vessel: 21 nTPM
- cervix: 21 nTPM
Single-cell type
- esophageal suprabasal cells: 55 nCPM
- extravillous trophoblasts: 51 nCPM
- esophageal basal cells: 51 nCPM
- cytotrophoblasts: 47 nCPM
- syncytiotrophoblasts: 46 nCPM
- migrating cytotrophoblasts: 45 nCPM
Immune cell
- non-classical monocyte: 31 nTPM
- NK-cell: 28 nTPM
- T-reg: 25 nTPM
- myeloid DC: 25 nTPM
- gdT-cell: 25 nTPM
- eosinophil: 24 nTPM
Brain region
- white matter: 19 nTPM
- pons: 18 nTPM
- hypothalamus: 17 nTPM
- midbrain: 16 nTPM
- spinal cord: 16 nTPM
- medulla oblongata: 16 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.89
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.82
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- TGS
- Small GTP-binding domain
- GTP binding domain
- GTP1/OBG, conserved site
- Beta-grasp domain superfamily
- TGS-like
- P-loop containing nucleoside triphosphate hydrolase
- OBG-type guanine nucleotide-binding (G) domain
- GTP binding protein, second domain
- Developmentally regulated GTP-binding protein
- 50S ribosome-binding GTPase
- TGS domain
- C-terminal region of MMR_HSR1 domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DRG2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DRG2 as an antibody target. Whether an autoantibody or antibody against DRG2 could matter depends on whether native DRG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DRG2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DRG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...